APZANRI Trademark

Trademark Overview


On Tuesday, December 19, 2023, a trademark application was filed for APZANRI with the United States Patent and Trademark Office. The USPTO has given the APZANRI trademark a serial number of 98322465. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Tuesday, February 11, 2025. This trademark is owned by Pfizer Inc.. The APZANRI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
apzanri

General Information


Serial Number98322465
Word MarkAPZANRI
Filing DateTuesday, December 19, 2023
Status731 - SECOND EXTENSION - GRANTED
Status DateTuesday, February 11, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 16, 2024

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, December 19, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10001-2192

Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10001-219

Trademark Events


Event DateEvent Description
Tuesday, December 19, 2023NEW APPLICATION ENTERED
Thursday, March 28, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, June 12, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 12, 2024ASSIGNED TO EXAMINER
Wednesday, June 26, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 16, 2024PUBLISHED FOR OPPOSITION
Tuesday, July 16, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 16, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 16, 2024PUBLISHED FOR OPPOSITION
Tuesday, September 10, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 11, 2025SOU TEAS EXTENSION RECEIVED
Tuesday, February 11, 2025SOU EXTENSION 1 FILED
Tuesday, February 11, 2025SOU EXTENSION 2 FILED
Tuesday, February 11, 2025SOU TEAS EXTENSION RECEIVED
Tuesday, February 11, 2025SOU EXTENSION 1 GRANTED
Tuesday, February 11, 2025SOU EXTENSION 2 GRANTED
Wednesday, February 12, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 12, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED